Tobias Gamper is an entrepreneur with a strong foundation in biomedical sciences and a deep commitment to translating scientific breakthroughs into impactful real-world solutions. He has led innovative research projects, including the discovery of novel antimicrobials from deep-sea organisms and the repurposing of the genetic engineering technique CRISPR for diagnostic cancer applications. At the Institute of Cancer Research, Tobias spearheaded pre-clinical R&D on targeted protein degraders (PROTACs) for paediatric medulloblastomas, gaining invaluable expertise in oncology and advanced therapeutic development.

Tobias holds a bachelor's degree in Biomedical Sciences and a master’s degree in Bioscience Entrepreneurship from University College London, where he developed a cost-effective CRISPR-based diagnostic test for Mycobacterium tuberculosis. He has been recognised for his entrepreneurial achievements through participation in esteemed accelerator programmes, including the VoXO Pioneer programme, the Westminster Big Idea Competition, Nucleate Activator, CRUK Cancer Tech Accelerator, as well as the Pioneer Group Launch Programme.

Tobias has led global market exploration and business development, securing over £395k in non-dilutive funding. His focus is on bringing Avigen's innovative services to market that address critical challenges in the biotech and pharmaceutical industries.